10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
10x Genomics, Inc. filed a Form 8-K under Item 7.01, Regulation FD Disclosure. The report concerns updates to patent litigation involving the company’s Chromium instruments, GEM microfluidic chips, Next GEM microfluidic chips, and related products. The report date was September 25, 2019, and it was signed on September 26, 2019.
Financial and Operating Metrics
The filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, or other financial metrics. It also does not quantify any potential financial impact from the disclosed litigation.
Material Changes Versus the Prior Comparable Period
- The U.S. International Trade Commission extended the target date for completing its investigation in the Bio-Rad Laboratories and Lawrence Livermore National Security patent dispute from the previously expected schedule to October 17, 2019.
- The Munich Region Court extended the deadline for issuing a ruling in the related Germany action to November 20, 2019.
Litigation, Outlook, Risks, and Unusual Items
In the ITC 1068 Action, the presiding judge previously found that 10x’s GEM microfluidic chips directly infringe three Bio-Rad patents, while finding no infringement by the company’s gel bead manufacturing chip and Next GEM microfluidic chip with respect to the claims at issue. The judge recommended an exclusion order and cease-and-desist order concerning imported GEM microfluidic chips.
The ITC was reviewing additional findings, including alleged indirect infringement and findings concerning the gel bead manufacturing and Next GEM microfluidic chips. A final determination was expected on or before October 17, 2019. The potential scope and financial consequences of any exclusion or cease-and-desist order are not quantified in the filing.
In the Germany Action, Bio-Rad alleged that 10x’s Chromium instruments, GEM microfluidic chips, and certain accessories infringe a German utility model. A ruling was expected on or before November 20, 2019.
Key Facts Investors Should Verify
- The ITC’s final determination and any exclusion or cease-and-desist orders issued after the filing.
- The status and outcome of the Germany Action and any resulting product restrictions.
- Whether the litigation affected sales, product availability, customer adoption, or regulatory and legal expenses.
- Any subsequent disclosure quantifying potential damages, contingencies, reserves, or other financial effects.